Skip to content
TrustList
Access Biotechnology logo
Investor

Access Biotechnology

Biotechnology investment arm of Access Industries backing private and public biopharma companies

Access Biotechnology cover

TrustList summary

Access Biotechnology is the life-sciences investment arm of Access Industries. It was set up in 2019 and puts money into companies developing therapies for conditions with high unmet need. The unit is led by Liam Ratcliffe, formerly head of worldwide clinical research and development at Pfizer.

Services

  • Private and public investments: stakes in biopharma companies across therapeutic areas, drug types and development stages.
  • Long-term backing: capital not tied to the normal life cycle of a venture fund, so investments can be held for years.
  • Company creation: it has co-incubated a company and co-led its seed round.
  • Partnership with founders: it works alongside management teams and other investors as the businesses grow.

Clients

Portfolio companies range from discovery-stage technology platforms to late-stage clinical programmes. Examples include firms working on iron metabolism disorders, inflammatory and allergic disease, immune disease, and inherited bleeding disorders.

Key facts

  • Founded: 2019
  • Portfolio: more than 40 private and public biotech companies
  • Track record: several backed firms have been acquired by large pharmaceutical groups

Summary written by TrustList from the business's own published information, Oct 2026.

Categories & features

Access Biotechnology rankings

Access Biotechnology is ranked on 3 TrustList rankings: #9 on 1, #36 on 1 and #40 on 1.

Every ranking orders its listings by their reviews, how complete the profile is and the Trust Score. Access Biotechnology has no reviews yet and 3 of the 10 profile details we look for. Where no listing on a page has been reviewed, the order follows the profiles alone.

Investor · 3 rankings

On 2 of these it sits behind Magnetic Ventures.

  • #9of 18
    Miami

    It is one of 2 here listing cloud and energy.

    Of the 18 here, 3 also cover seed stage and 3 also cover partners; 11 also work in New York City and 9 also work in London.

  • #36of 151
    London

    It is one of 4 here listing energy and one of 5 here listing cloud.

    Of the top 59 here, 10 also cover healthtech and 9 also cover series a; 16 also work in San Francisco and 12 also work in Hong Kong.

    Behind Puma Private Equity, ahead of Coutts.

  • #40of 156
    New york city

    It is one of 3 here listing energy and one of 4 here listing cloud.

    Of the top 58 here, 10 also cover artificial intelligence and 8 also cover biotech; 10 also work in Silicon Valley and 9 also work in Chicago.

As of 2026-11-16. Organic ranks only; sponsored placements are never ranks. How TrustList ranks

What the business tells TrustList

Founded
2019 (7 years) evidence sent

Ask TrustList to introduce you to Access Biotechnology

TrustList reads every request before passing it on, and sends it only where the funder's stage and focus look like a fit. We do not charge for introductions, and we cannot promise a reply.

Protected by reCAPTCHA - Google Privacy Policy and Terms apply.

Reviews

Write the first review of Access Biotechnology

Used it? Your experience helps other buyers decide.

Write a review

Questions & answers

No questions yet. Be the first to ask about Access Biotechnology.

Access Biotechnology alternatives

Similar listings buyers compare against this one.

Investment company buying stakes in undervalued micro-cap stocks and pushing for change to release value

Capital and advisory firm for blockchain projects, part of Faculty Group

Technology investor backing fast-growing, high-margin companies in fintech and other large markets

Early-stage venture capital firm backing deep technology founders in Israel, Europe and the United States

Early-stage venture firm backing pre-seed and seed founders in Canada and the US

Investor in software-led teams aiming to automate large parts of the world across any sector or country

Asia Pacific venture capital firm investing in technology-related companies since 1990

Venture investor backing entrepreneurs who improve people's financial health